Circular RNA_0078767 upregulates Kruppel-like factor 9 expression by targeting microRNA-889, thereby inhibiting the progression of osteosarcoma

Bioengineered. 2022 Jun;13(6):14313-14328. doi: 10.1080/21655979.2022.2084257.

Abstract

Among kids and juveniles, osteosarcoma (OS) is a common bone malignancy. Circular RNAs (circs, circRNAs) play important roles in multiple malignancies including OS, yet circ_0078767's biological functions in OS are far from well elucidated. This study is targeted at understanding circ_0078767's biological functions in OS and its molecular mechanisms. This study confirmed that circ_0078767 expression was reduced in OS cell lines and tissues. Circ_0078767 overexpression remarkably inhibited OS cell growth, migration, invasion, epithelial-mesenchymal transition (EMT), and promoted apoptosis, whereas circ_0078767 knockdown resulted in the opposite effects. MicroRNA-889 (miR-889) was targeted and regulated by circ_0078767, and miR-889 could negatively modulate Kruppel-like factor 9 (KLF9) expression. Besides, circ_0078767 positively regulated KLF9 expression in OS cells via repressing miR-889. In conclusion, circ_0078767 enhances KLF9 expression by targeting miR-889 to inhibit OS progression.

Keywords: KLF9; MiR-889; Osteosarcoma; circ_0078767.

MeSH terms

  • Bone Neoplasms* / genetics
  • Bone Neoplasms* / metabolism
  • Bone Neoplasms* / pathology
  • Cell Line, Tumor
  • Cell Proliferation / genetics
  • Disease Progression
  • Humans
  • Kruppel-Like Transcription Factors* / genetics
  • Kruppel-Like Transcription Factors* / metabolism
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Osteosarcoma* / genetics
  • Osteosarcoma* / metabolism
  • Osteosarcoma* / pathology
  • RNA, Circular* / genetics
  • RNA, Circular* / metabolism

Substances

  • KLF9 protein, human
  • Kruppel-Like Transcription Factors
  • MIRN889 microRNA, human
  • MicroRNAs
  • RNA, Circular

Grants and funding

The author(s) reported there is no funding associated with the work featured in this article.